ProKidney Corp. (NasdaqCM: PROK)
Health Care · Biotechnology · US
$1.74
+1.16% today · -41.8% 1Y
ProKidney Corp. (NasdaqCM: PROK) operates in the Biotechnology industry within the Health Care sector. The company is valued at $363.53M and employs 231 people.
Over the last twelve months the share price has lost 41.8%, trading between 1.30 and 3.48.
Tweenvest scores ProKidney Corp. across four factors: quality 50/100, value 52/100. Its strongest factor is value.
PROK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $363.53M
- Revenue (TTM)
- $818.00K
- P/E
- —
- EPS
- -0.56
- Dividend yield
- —
- Beta (5Y)
- 1.80
- 52-week high
- $3.48
- 52-week low
- $1.30
- Avg volume (3M)
- —
- Shares outstanding
- 208.93M
- Employees
- 231
- Next earnings
- —
About ProKidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
- ISIN
- US74291D1046
- Founded
- 2015
- Listed since
- Jun 30, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Formycon AGXTRA: FYB | $377.16M | €19.06 | -1.75% |
| Fennec Pharmaceuticals Inc.NasdaqCM: FENC | $375.57M | $10.71 | +5.00% |
| Hansa Biopharma AB (publ)OM: HNSA | $365.97M | Skr35.96 | +8.38% |
| Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA | $364.07M | $12.50 | +3.31% |
| Emergent BioSolutions Inc.NYSE: EBS | $361.99M | $7.06 | +3.67% |
| PureTech Health plcLSE: PRTC | $360.13M | £1.11 | +2.97% |
| Inhibikase Therapeutics, Inc.NasdaqCM: IKT | $358.69M | $1.97 | -1.50% |
| Cuorips Inc.TSE: 4894 | $353.89M | ¥6,310.00 | +0.80% |
Figures last refreshed Oct 11, 2026.